Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.

Saved in:
Bibliographic Details
Title: Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.
Authors: Matsumoto J; Department of Personalised Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: matsumotoj@okayama-u.ac.jp., Takeda T; Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Education and Research Centre for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: takeda-t@okayama-u.ac.jp., Sugimoto S; Department of Personalised Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: p4o64sue@s.okayama-u.ac.jp., Sakai T; Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: t-sakai@okayama-u.ac.jp., Loyao BB; Department of Personalised Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Pharmacy, School of Health Care Professions, University of San Carlos, Talamban, Cebu City, Cebu 6000, Philippines. Electronic address: pmu589iw@s.okayama-u.ac.jp., Higashionna T; Department of Pharmacy, Okayama University Hospital, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: t.higashionna@cc.okayama-u.ac.jp., Hamano H; Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Pharmacy, Medical Development Field, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: hamano.hirofumi@okayama-u.ac.jp., See GLL; Department of Pharmacy, School of Health Care Professions, University of San Carlos, Talamban, Cebu City, Cebu 6000, Philippines. Electronic address: glsee@usc.edu.ph., Ariyoshi N; Department of Personalised Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: ariyoshi-n@okayama-u.ac.jp., Zamami Y; Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan; Department of Pharmacy, Medical Development Field, Okayama University, 2-5-1 Shikata, Kita-ku, Okayama 700-8558, Japan. Electronic address: zamami-y@okayama-u.ac.jp.
Source: Leukemia research [Leuk Res] 2026 Jul; Vol. 166, pp. 108236. Date of Electronic Publication: 2026 Apr 15.
Publication Type: Journal Article; Comparative Study
Journal Info: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-5835
DOI:10.1016/j.leukres.2026.108236